Product Name: Dulaglutide
Form: Free base
CAS No: 923950-08-7
Molar Mass: 3314.62
Chemical Formula: C149H221N37O49
Synonyms: LY 2189265, Trulicity
Storage: Store at -20℃
Sequence: HGEGTFTSDV SSYLEEQAAK EFIAWLVKGG GGGGGSGGGG SGGGGSAESKYGPPCPPCPA PEAAGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSQEDPEVQFNWYVDG VEVHNAKTKP REEQFNSTYR VVSVLTVLHQ DWLNGKEYKCKVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN QVSLTCLVKGFYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGNVFSCSVMHEA LHNHYTQKSL SLSLG
Target: GLP-1 RA
Application: Dulaglutide (CAS number 923950-08-7) is a potent pharmaceutical compound extensively employed in the management of type 2 diabetes. This glucagon-like peptide-1 receptor agonist (GLP-1 RA) plays a pivotal role in diabetes treatment by mimicking the action of endogenous GLP-1. Acting on the GLP-1 receptor, Dulaglutide stimulates insulin secretion and inhibits glucagon release, leading to improved blood glucose control. Beyond its glycemic benefits, Dulaglutide has demonstrated positive effects on cardiovascular outcomes, making it a versatile therapeutic option. In the pharmaceutical realm, it stands out for its dual action in glycemic control and cardiovascular risk reduction, contributing significantly to comprehensive diabetes care. The compound's efficacy and multifaceted benefits underscore its importance in the evolving landscape of diabetes therapeutics.
Current Research:
Dulaglutide is a once-weekly GLP-1 receptor agonist that has gained prominence in the treatment of type 2 diabetes. Known for its efficacy in controlling blood glucose levels, it also offers significant cardiovascular benefits, making it an essential part of diabetes management. As research progresses, dulaglutide is being studied for its broader therapeutic potential, including its effects on obesity, neurodegenerative diseases, and its compatibility with other treatments. This multi-faceted approach has made it a subject of growing interest in both clinical practice and ongoing research.
Mechanism of Action
Dulaglutide is a GLP-1 receptor agonist that works by enhancing glucose-dependent insulin secretion, inhibiting glucagon release, and slowing gastric emptying. These actions help regulate blood sugar levels, particularly after meals, making it effective in managing type 2 diabetes. It also reduces body weight, which can be beneficial for patients with obesity or overweight conditions, as part of a broader metabolic control strategy.
Cardiovascular Benefits
Recent research has highlighted dulaglutide's cardiovascular benefits, particularly in reducing the risk of major adverse cardiovascular events (MACE). Studies have shown that the drug significantly lowers the incidence of heart attacks, strokes, and cardiovascular-related deaths in patients with type 2 diabetes. These findings suggest that dulaglutide not only manages glycemic control but also provides long-term protection for cardiovascular health.
Weight Loss and Obesity Management
Dulaglutide has been shown to aid in weight loss, which is beneficial in managing obesity, a common comorbidity of type 2 diabetes. Studies have demonstrated that it leads to significant reductions in body weight, even in patients without diabetes. The medication helps with appetite regulation and promotes feelings of satiety, which supports long-term weight management.
Neuroprotective Potential
In addition to its use in metabolic and cardiovascular diseases, emerging research has suggested that dulaglutide may have neuroprotective effects. Activation of GLP-1 receptors has been linked to reduced neuroinflammation and decreased amyloid plaque formation, both of which are important in the context of neurodegenerative diseases like Alzheimer's and Parkinson's. This emerging area of research could expand dulaglutide's therapeutic applications beyond diabetes and cardiovascular diseases.
Safety and Tolerability
Dulaglutide is generally well tolerated, with most side effects being gastrointestinal, such as nausea, diarrhea, and vomiting. These effects tend to lessen over time as the body adapts to the medication. Serious adverse events are rare, and long-term use has been shown to be safe for most patients. However, as with any medication, regular monitoring and individualized treatment plans are important to minimize risks.
Combination Therapy
Recent studies have explored the potential of combining dulaglutide with other anti-diabetic medications, such as SGLT2 inhibitors. This combination has been found to offer enhanced glycemic control, leading to a more significant reduction in HbA1c compared to either drug used alone. This approach offers promising results for patients who struggle with blood sugar control using monotherapy.
Reference:
Get a Quote
LinkPeptide
